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Inflammation and lipid signaling are intertwined modulators of homeostasis and immunity. In addition to the
extensively studied eicosanoids and inositol phospholipids, emerging studies indicate that many other lipid
species act to positively and negatively regulate inflammatory responses. Conversely, inflammatory
signaling can significantly alter lipidmetabolism in the liver, adipose tissue, skeletal muscle, andmacrophage
in the context of infection, diabetes, and atherosclerosis. Here, we review recent findings related to this
interconnected network from the perspective of immunity and metabolic disease.Introduction
Insulin resistance is a major metabolic abnormality in the great
majority of patients with type 2 diabetes, and the incidence of
this disease has reached epidemic proportions around the globe
(Hupfeld et al., 2010; Kahn et al., 2006). Obesity is clearly the
most common cause of insulin resistance, and it is the parallel
epidemic of obesity, which is driving the rising incidence of
type 2 diabetes (Kahn et al., 2006). The etiology of insulin resis-
tance has been intensely studied (Qatanani and Lazar, 2007;
Shulman, 2000), and it is now recognized that chronic tissue
inflammation is an important cause of obesity-induced insulin
resistance (Attie and Scherer, 2009; Lumeng and Saltiel, 2011;
Olefsky and Glass, 2010; Shoelson et al., 2007). One of the initial
lines of evidence for this relationship derived from the unex-
pected observations that TNFa, a cytokine associated with
cachexia in cancer, was elevated in obese adipose tissue in
rodents and that inhibition of this cytokine improved glucose
tolerance and insulin sensitivity (Hotamisligil et al., 1993). Subse-
quently, studies demonstrated that a key mechanism underlying
obesity-induced inflammation is the accumulation of increased
numbers of tissue macrophages, particularly in obese adipose
tissue (Weisberg et al., 2003; Xu et al., 2003). These adipose
tissue macrophages (ATMs) can span the spectrum from the
most proinflammatory, M1-like cells to anti-inflammatory,
M2-like macrophages (Lumeng et al., 2007a, 2007b; Nguyen
et al., 2007). The proinflammatory ATMs are often referred
to as classically activated macrophages (CAMs), while the anti-
inflammatory macrophages are referred to as alternatively
activated macrophages (AAMs).
In obesity, the balance is tilted toward the M1-like macro-
phage polarization state (Lumeng et al., 2007a), and these cells
secrete a number of different cytokines, such as tumor necrosis
factor a (TNFa), interleukin-1b (IL-1b), etc. In turn, these cyto-
kines can act through paracrine mechanisms to directly inhibit
insulin action in insulin target cells (i.e., hepatocytes, myocytes,
and adipocytes) (Fe`ve and Bastard, 2009; Hotamisligil, 1999). It
is also possible that these tissue cytokines leak into the systemic
circulation to cause insulin resistance through endocrine effects.
Cytokine signaling activates stress kinases such as S6K, IKKb,JNK1, and PKCF, which phosphorylate IRS1 on inhibitory serine
residues and results in impaired downstream signaling (Hotami-
sligil, 2006; Schenk et al., 2008). Cytokines can also inhibit insulin
action through transcriptional mechanisms by decreasing the
expression levels of key insulin signaling molecules (Stephens
and Pekala, 1992). Finally, cytokines can promote ceramide
biosynthesis, which directly inhibits Akt activation, as discussed
below (Holland et al., 2011).
While ATMs are considered to be the ultimate effector cell
elaborating cytokines that cause insulin resistance, their recruit-
ment to adipose tissue and their activation state are influenced
by other immune cell types that populate obese adipose tissue,
including T cells, B cells, eosinophils, and mast cells (Feuerer
et al., 2009; Kintscher et al., 2008; Liu et al., 2009; Nishimura
et al., 2009; Winer et al., 2011; Wu et al., 2011). However, inflam-
mation is not the only mechanism of insulin resistance in obesity.
For example, various abnormalities of lipid metabolism have
been described which can also impair insulin signaling (Itani
et al., 2002; Savage et al., 2007). These lipotoxic effects include
the production of intracellular lipid mediators, such as diacylgly-
cerols (Samuel et al., 2010), as well as more direct effects of
circulating saturated fatty acids. However, chronic tissue inflam-
mation and lipid abnormalities are not completely separable
processes, and these two systems are closely intertwined and
each can amplify the other in the in vivo pathophysiologic setting.
In this review, we focus on the interconnections between
abnormal lipid signaling and proinflammatory pathways in insulin
resistant states.
Effects of Fatty Acids on Inflammation
Saturated Fatty Acids
Circulating free fatty acids (FFAs) are typically elevated in insulin
resistant states, and dietary fat intake has an important influence
on the composition of these FFAs (Fielding et al., 1996). The
association between elevated FFA levels and insulin resistance
is well known (Park et al., 2007), and numerous studies have
demonstrated that infusions of triglyceride emulsions plus
heparin to rapidly raise FFA levels will cause a decrease in insulin
sensitivity (Boden et al., 1991; Roden et al., 1996; Staehr et al.,Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 635
Figure 1. The Effects of Fatty Acids on
Inflammation and Insulin Resistance
Saturated fatty acids (SFAs) stimulate inflamma-
tory pathways through Tlr4-dependent and -inde-
pendent mechanisms. SFAs are also precursors
for ceramide biosynthesis, and inflammatory
pathway stimulation by SFAs, as well as cytokines,
induces the enzymes that produce ceramide,
providing twomechanisms for increased ceramide
content. Omega 3 FAs produce anti-inflammatory
effects by stimulating GPR120 and production of
resolvins and protectins. Omega 6 FAs can be
proinflammatory through their metabolism to
leukotrienes and prostaglandins.
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immune cell types in adipose tissue are exposed to high local
concentrations of FFAs released from adipocytes by lipolysis.
In this way, these cells exist within a lipid-rich environment that
could amplify the effects of saturated fatty acids (SFAs) within
adipose tissue.
SFAs are proinflammatory lipid compounds, with many
studies demonstrating that treatment of various cell types with
SFAs broadly activates inflammatory signaling in macrophages,
adipocytes, myocytes, hepatocytes, etc. (Hwang and Rhee,
1999; Nguyen et al., 2005, 2007; Yu et al., 2002). This leads to
stimulation of IKKb/NFkB and JNK1/AP1, as well as release of
cytokines (Figure 1). Several laboratories have independently
reported that proinflammatory effects of SFAs are mediated, at
least in part, through activation of Tlr4 and/or Tlr2 (Lee et al.,
2001; Nguyen et al., 2007; Schaeffler et al., 2009; Senn, 2006;
Shi et al., 2006). Tlr2 and Tlr4 are members of the Tlr family of
receptors that recognize pathogen-associated molecular
patterns (PAMPs), as well as endogenously derived indicators
of tissue injury (Kumar et al., 2009). Tl4 ligands include lipopoly-
saccharide (LPS), a component of the cell walls of gram-negative
bacteria, while Tlr2 ligands include the lipoteichoic acid compo-
nent of gram-positive bacteria (Kumar et al., 2009; Poltorak et al.,
1998). In the absence of Tlr4, SFA-mediated inflammatory
signaling is abrogated in adipocytes (Shi et al., 2006). Further-
more, Tlr4 knockout (KO) mice are resistant to the effects of
high-fat diets to cause decreased insulin sensitivity (Saberi
et al., 2009; Shi et al., 2006) (Figure 1). As an additional aspect
of Tlr4-mediated inflammation, it has been reported that obesity
is associated with gastrointestinal dysbiosis in which LPS
derived from gastrointestinal-tract microflora leaks into the
systemic circulation (Brun et al., 2007; Creely et al., 2007).
It has been suggested that the reported effects of SFAs on
widely used indicators of Tlr4 activation in macrophages, such
as TNFa, are due to contamination of the serum or albumin
used in these experiments with endotoxin (Erridge and Samani,
2009). While this may account for some of the effects reported
in cultured macrophages, infusion of heparin/lipid emulsions636 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.results in Tlr4-dependent inflammatory
responses in adipose tissue (Shi et al.,
2006). Collectively, there is substantial
evidence for functionally important rela-
tionships between SFAs, Tlr signaling,
and insulin resistance, but the molecular
mechanisms remain unclear. Structuralconsiderations (Park et al., 2009) and direct binding assays
(Schaeffler et al., 2009) argue against the possibility that SFAs
are direct ligands for Tlr4. There are several ways in which
SFAs could indirectly activate Tlr signaling. One possibility is
through interaction with SFA binding proteins that function as
Tlr coreceptors. A precedent for this type of mechanism is
provided by the ability of CD36, a fatty acid transporter and ox-
idzed low-density lipoprotein (LDL) receptor, to interact with Tlr2
and induce signaling in response to oxidized LDL (Seimon et al.,
2010; Stewart et al., 2010). SFAs have also been reported to
induce Tlr4-depedent gene expression by promoting dimeriza-
tion of Tlr4, a necessary step in receptor activation, within
specialized lipid domains termed ‘‘lipid rafts’’ in macrophages
(Figure 1) (Wong et al., 2009). This appears to be dependent on
the ability of SFAs to stimulate NADPH oxidase production of
reactive oxygen species (ROS). In independent studies, SFA
treatment led to membrane redistribution of c-Src so that it is
now concentrated in lipid rafts, where it becomes activated
(Holzer et al., 2011). This then leads to stimulation of JNK1 and
its proinflammatory target genes (Figure 1). It is possible that
the dimerization of Tlr4 and the redistribution of c-Src in lipid rafts
upon SFA treatment are mechanistically related events,
providing a pathway for SFA-induced proinflammatory signaling.
A third possibility is that SFAs may stimulate the production or
release of a tissue damage signal that is sensed by Tlrs. There
are a number of endogenously derived molecules that have
been shown to exert these types of functions when released
from necrotic or damaged cells, such as high-mobility group
proteins (Park et al., 2004). In concert, substantial additional
work will be required to fully establish themolecular mechanisms
linking SFAs to Tlr signaling.
SFAs can also stimulate stress and/or inflammatory pathways
by Tlr-independent mechanisms. Treatment of macrophages
with SFAs leads to an increase in ROS production and this can
activate a number of stress kinases. The ability of SFAs to
increase ROS levels may also drive stimulation of the NLRP3
(nucleotide-binding domain, leucine-rich repeats containing
family, pyrin domain-containing 3) inflammasome (Wen et al.,
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(apoptotic speck protein containing a caspase recruitment
domain) that regulates caspase 3-dependent cleavage of
pro-IL-1b to release active IL-1b (Ting et al., 2008). Recent
studies have demonstrated that SFA-induced ROS can activate
the NLRP3-ASC inflammasome complex, thereby increasing
release of IL-1b (Wen et al., 2011). When applied to insulin target
cells, IL-1b can decrease insulin signaling, providing another
mechanism for SFA-mediated inflammatory responses causing
insulin resistance. Indeed, NLRP3, ASC, and caspase 1
knockout mice are all protected from high-fat diet-induced
inflammation and insulin resistance (Wen et al., 2011).
Finally, SFAs are precursors to other lipid products, such
as DAGs, and intracellular levels of DAGs can be increased in
insulin resistant states (Kumashiro et al., 2011). This can lead
to PKC activation with decreased insulin signaling, and this
concept has been the subject of recent reviews (Samuel et al.,
2010). Taken together, these mechanisms would explain an
important component of ‘‘lipotoxicity’’ in which SFAs promote
the chronic tissue inflammatory state that can cause insulin
resistance.
In addition to stimulating inflammatory pathways, SFAs can
lead to decreased insulin sensitivity through other mechanisms.
For example, SFAs are precursors for ceramide biosynthesis,
and ceramide can directly cause decreased insulin signaling,
as discussed in more detail below (Stratford et al., 2004;
Summers, 2010; Ussher et al., 2010). Finally, FetuinA is a glyco-
protein primarily made in hepatocytes and secreted into the
circulation. In vitro studies have demonstrated that SFA treat-
ment of hepatocytes leads to increased FetuinA messenger
RNA (mRNA) expression and secretion, and other studies have
indicated that FetuinA can directly inhibit the early steps of
insulin signaling (Dasgupta et al., 2010).
Ceramide Metabolism
Lipid and inflammatory pathway signaling are closely intertwined
processes that can result in insulin resistance. One important
crossroad between these two pathways, relevant to the devel-
opment of decreased insulin sensitivity, involves ceramide
biosynthesis. Many papers have demonstrated strong associa-
tions between intracellular ceramide levels and the development
of insulin resistance (Holland et al., 2011; Stratford et al., 2004;
Ussher et al., 2010). For example, the saturated fatty acid
palmitate is a preferential substrate leading to the biosynthesis
of ceramide, providing another potential mechanism for SFA-
induced insulin resistance (Ussher et al., 2010). Elevated intra-
cellular ceramide levels can stimulate the ability of phosphatase
2A to dephosphorylate Akt, and this inhibits insulin signaling,
providing a mechanism for ceramide-mediated insulin resis-
tance (Stratford et al., 2004). Recent studies have revealed
a further role for ceramide at the nexus of inflammation and
lipid signaling. Thus, independent of their roles as precursors
for ceramide biosynthesis, SFA stimulation of the Tlr4 pathway
causes an increase in expression of the enzymes involved in
ceramide biosynthesis (Holland et al., 2011). Other nonlipid
Tlr4 agonists, such as LPS, have a similar effect. Interestingly,
stimulation with TNFa recapitulated the increased ceramide
biosynthesis (Dbaibo et al., 2001; Holland et al., 2011), and
these authors showed that the effect of Tlr4 and TNFa signaling
on ceramide biosynthesis was IKKb dependent, directly demon-strating how inflammatory pathway signaling inputs can promote
biosynthesis of a lipid moiety, i.e., ceramide, which directly
inhibits insulin signaling (Figure 1).
Omega 3 Fatty Acids
While SFAs promote inflammation and insulin resistance, other
classes of fatty acids can have beneficial effects. For example,
long-chain polyunsaturated omega 3 FAs, such as DHA and
EPA, can exert anti-inflammatory effects, and this has been
known for many years (Calder, 2006; Lang et al., 2003; Polozova
and Salem, 2007; Proudman et al., 2008; Weldon et al., 2007).
However, the mechanisms for these effects have been poorly
understood until recently. There is a family of lipid sensing
GPCRs, including GPR40, 41, 43, 84, and 120 (Itoh et al.,
2003; Tazoe et al., 2008; Wang et al., 2006), and recent reports
have indicated that omega 3 FAs can stimulate GPR120 (Hira-
sawa et al., 2005; Oh et al., 2010). With respect to inflammation,
omega 3 FAs are ligands for GPR120 and can exert robust and
broad anti-inflammatory effects in various macrophage types
(Oh et al., 2010). For example, when RAW267.4 cells or intraper-
itoneal macrophages are treated with Tlr4/2 agonists or TNFa,
potent stimulation of inflammatory pathways occurs. However,
when macrophages are pretreated with omega 3 FAs, these
proinflammatory effects are inhibited (Lee et al., 2003), and
these anti-inflammatory effects are completely abrogated in
the absence of GPR120 (Oh et al., 2010). These studies show
that omega 3 FAs are ligands for GPR120 and exert anti-inflam-
matory effects by signaling through this receptor. In this sense,
GPR120 emerges as a receptor/sensor for this anti-inflammatory
class of fatty acids.
The mechanisms for this effect are also of interest. TAK1 is
a proximal kinase in these proinflammatory pathways and in
response to inflammatory signals, the adaptor protein TAB1
associates with and activates TAK1, stimulating both the IKKb/
NFkB and the JNK/AP1 pathways. Activation of GPR120 by
omega 3 FAs specifically inhibits TAK phosphorylation and acti-
vation, providing a mechanism for the broad inhibition of Tlr and
TNF signaling (Oh et al., 2010). b arrestins are a family of mole-
cules that can serve as adaptor or scaffold proteins for a number
of different GPCRs (Luttrell and Lefkowitz, 2002). Interestingly,
omega 3 FA stimulation leads to direct association between
GPR120 and b arrestin-2 and the anti-inflammatory effects of
GPR120 are completely b arrestin-2 dependent. The apparent
mechanism for this is that DHA stimulation leads to GPR120/b
arrestin-2 association with subsequent internalization of the
complex. The internalized b arrestin-2 then associates with
TAB1, ‘‘stealing’’ it from the TAK1 complex, leading to inactiva-
tion of TAK1 with inhibition of downstream inflammatory
signaling to IKKb/NFkB and JNK/AP1 (Oh et al., 2010) (Figure 2).
These cellular mechanisms translate to the in vivo situation.
Thus, omega 3 FA treatment of WT obese mice led to marked
in vivo anti-inflammatory and insulin sensitizing effects, but no
such effects were observed in obese GPR120 KO animals.
Therefore, it appears that an important mechanism for the anti-
inflammatory effects of omega 3 FAs operates through the
GPR120 signaling pathway in macrophages.
It is possible that additional mechanisms also exist which
could participate in the anti-inflammatory effects of omega 3
FAs. For example, these FAs can be metabolized to small lipid
mediators termed ‘‘protectins/resolvins,’’ and studies haveCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 637
Figure 2. Omega 3 Fatty Acids and the GPR120 Signaling Pathway
(A) Tlr4 and TNF receptor signaling stimulates the TAK1/TAB1 complex which
then activates IKKb and MKK4 to stimulate the downstream NFkB and JNK1
inflammatory pathways.
(B) Omega 3 FAs activate GPR120 causing it to associate with b arrestin-2. The
GPR120db arrestin-2 complex then undergoes endocytosis and the internal-
ized b arrestin-2 binds to TAB1, ‘‘stealing’’ it from the TAK1 complex, causing
TAK1 inactivation with inhibition of subsequent downstream proinflammatory
signaling. Adapted from Oh et al. (2010).
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can produce anti-inflammatory effects (Serhan and Chiang,
2008; Serhan et al., 2008) (Figure 1). Furthermore, in vivo studies
in mice also indicate anti-inflammatory effects through the resol-
vin/protectin system. Finally, omega 3 FAs are metabolized
through a variety of lipid biosynthetic pathways and can inhibit
the production of arachidonic acid and other proinflammatory
eicosanoids.
Palmatoleate
Palmatoleate (C16:1N7) is a nutritional component of many
food stuffs and can also be produced by de novo lipogenesis.
Circulating C16:1N7 levels are directly correlated with insulin
sensitivity in mice and that inhibition of C16:1N7 production
can cause insulin resistance (Cao et al., 2008). Based on this
work, they suggest that C16:1N7 is a lipokine secreted from
adipocytes that can modulate glucose homeostasis in muscle
and liver through endocrine effects. When added to cells638 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.C16:1N7 can produce insulin-like effects and these may relate
to GPR120 in adipocytes. C16:1N7 is a GPR120 agonist and,
in adipocytes, it stimulates glucose transport through a Gaq-
dependent signaling pathway that leads to GLUT4 translocation.
Effects of Inflammation on Lipid Metabolism
While the impact of inflammation on gene expression has been
studied in a variety of tissues and cell types, much less is known
regarding the influence of inflammation on the vast repertoire of
lipids that function as structural components of cell membranes,
sources of energy, and signaling molecules. Notable exceptions
are provided by the eicosanoids and inositol phospholipids,
which have been subjected to extensive analysis based on
their roles as essential signaling molecules in diverse aspects
of development, homeostasis, and immunity. For example, pros-
taglandins represent a class of eiconsanoids that are generated
from arachidonic acid in membrane phospholipids through the
sequential actions of phospholipase A and cyclooxygenase
enzymes. Both classes of enzymes are under direct control by
signaling pathways that respond to PAMPs and inflammatory
cytokines, enabling rapid and robust increases in prostaglandin
generation. The resulting prostaglandin metabolites have
diverse biological roles, including amplification of inflammatory
responses that contribute to the ‘‘cardinal signs’’ of inflammation
(redness, heat, pain, and swelling). In the case of the inositol
phospholipids, extensive work over the past decade has re-
vealed diverse roles of phosphatidylinositol 3 kinases, particu-
larly PI3Kg and PI3Kd, in responding to inflammatory signals
to orchestrate specific aspects of innate and adaptive immune
responses. These topics have been the focus of recent
reviews (Dennis et al., 2011; Fung-Leung, 2011; Ghigo et al.,
2010; Ricciotti and FitzGerald, 2011).
In contrast, knowledge of effects of inflammation on metabo-
lism of most other classes of lipids remains at a relatively
rudimentary level. In this section, we discuss the impact of
inflammation on lipid metabolism from the perspective of the
relationship between inflammation and metabolic disease. We
begin with a brief description of the effects of innate immunity-
driven inflammation on lipid metabolism at the whole-body level,
and then consider effects at the organ and cellular level in the
liver, adipose tissue, skeletal muscle, and macrophage. We
conclude this section with a discussion of the intersection of
inflammatory signaling pathways with transcription factors that
control cholesterol and fatty acid biosynthesis.
Inflammation and Lipid Metabolism at the Whole-Body
Level
At the whole-body level, inflammation initiated by severe bacte-
rial and viral infection can result in marked changes in lipid
and lipoprotein metabolism. For example, infection with gram-
negative organisms has long been known to induce marked
hypertriglyceridemia and elevated circulating free fatty acid
levels (Gallin et al., 1969). Although these changes are likely to
reflect metabolic adaptations that enable the host to resist infec-
tion, there is also evidence that high-density lipoproteins (HDLs)
and triglyceride-rich lipoproteins themselves function to bind
and neutralize bacterial endotoxins (Harris et al., 2000). Experi-
mental studies using LPS to mimic infection indicate that
increases in very low-density lipoproteins (VLDLs) account for
the majority of the rise in serum triglycerides, resulting from
Figure 3. Impact of Inflammation on Lipid
Metabolism
Inducers and amplifiers of inflammation include
ligands for pattern recognition receptors (e.g.,
LPS), cytokines (e.g., IL-1b), and saturated fatty
acids (SFAs). Each of these inflammatory stimuli
influence lipid metabolism in liver, skeletal muscle,
and adipose tissue by acting on both parenchymal
cells and resident immune cells. Although some
effects are seen in all three organs (e.g., increased
TG hydrolysis), other effects may be organ specific
(e.g., increased fatty acid biosynthesis in liver).
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et al., 1992b). The hyperlipidemia of sepsis was initially consid-
ered to be a consequence of catecholamine release, which
stimulate release of free fatty acids from adipose tissue that
are taken up by the liver, metabolized and released in VLDL
particles (Nonogaki et al., 1994). In addition, TNFa was found
to suppress lipoprotein lipase synthesis, which could contribute
to hypertriglyceridemia by decreasing the rate of triglyceride
clearance in the periphery (Figure 3) (Kawakami et al., 1987).
Additional cell-autonomous mechanisms also contribute to
increased lipolysis, as discussed in further detail below.
In addition to the potential roles of SFAs as endogenous
activators of Tlr signaling, low levels of endotoxin derived from
bowel flora are present in the portal circulation, with levels
varying dependent on various factors, including diet (Amar
et al., 2008; Ba¨ckhed et al., 2004). The concentration of LPS
required to increase VLDL secretion is orders ofmagnitude lower
than that required to induce sepsis, raising the possibility that
endogenous endotoxins may contribute to low levels of Tlr4 acti-
vation (Feingold et al., 1992b). A recent study of Tlr4/ mice
indicated a modestly exaggerated hypoglycemic response to
fasting and elevated levels of circulating and skeletal muscle
triglycerides. No effect on insulin sensitivity was observed,
suggesting a role of Tlr4 in glucose and lipid metabolism inde-
pendent of insulin during fasting (Pang et al., 2010).
Toll-like receptors, including Tlr4, aremost highly expressed in
cells that play direct roles in innate immune responses, such as
macrophages, that are major sources of cytokines and chemo-
kines in the setting of infection and tissue injury. However, Tlrs
are also expressed on a broad range of other cells types,
including adipocytes, hepatocytes, and skeletal muscle cells
(e.g., Lang et al., 2003; Matsumura et al., 2000; Shi et al.,
2006). The expression of Tlrs in these cells may enable them to
complement the functions of specialized immune cells through,
for example, the production of chemokines and cytokines.
Recent studies further suggest that Tlr signaling within paren-
chymal cells of the liver, adipose tissue and skeletal muscle
serves to modulate diverse aspects of their specific roles inCell Metabolismmetabolism. As noted above, inhibitory
effects of LPS and cytokines such as
TNFa and IL-1b on insulin signaling path-
ways are well established (reviewed in
Olefsky and Glass, 2010). Inhibition of
insulin signaling can itself potentially
impact on lipid metabolism, but there is
substantial evidence that inflammatorysignaling pathways affect many aspects of lipid metabolism
independently of their effects on insulin. For example, direct
infusion of a relatively low dose of TNFa into normal human
subjects increased whole body lipolysis by 40% and a corre-
sponding increase of free fatty acids over a 4 hr time period
(Plomgaard et al., 2008). No changes in glucose homeostasis
were observed in this acute treatment protocol.
Because Tlr4 signaling stimulates expression of a broad range
of cytokines that are linked to insulin resistance, such as TNFa
and IL-1b, it will be of particular interest to tease apart direct
and indirect effects on lipid homeostasis in specific cell types
in vivo. Bone marrow reconstitution experiments, in which
wild-type bone marrow was replaced with Tlr4-deficient bone
marrow, conferred protection against diet/obesity-induced
insulin resistance, consistent with important roles in macro-
phages and other bone marrow-derived cells (Saberi et al.,
2009). However, these studies did not address the effects of
hematopoietic deletion of Tlr4 signaling on lipid metabolism.
In addition to contributing to development of insulin resis-
tance, Tlrs have been shown to contribute to the development
of atherosclerosis (reviewed in Coban et al., 2009; Curtiss and
Tobias, 2009; Olefsky and Glass, 2010). In this context, Tlr-
driven inflammation is thought to contribute to pathology by
amplifying recruitment of macrophages and other immune cells
to atherosclerotic lesions and to influence processes that
promote modifications of LDL that increase its uptake by
macrophages and smooth muscle cells, such as oxidation
(reviewed in Rocha and Libby, 2009). As discussed in further
detail below, studies in cell culture models suggest important
effects of Tlr4 signaling in hepatocytes, skeletal muscle cells,
and adipocytes. Development of a conditional allele of Tlr4
would be a valuable resource for investigation of direct and
indirect effects of Tlr4 engagement in tissues other than the
hematopoietic system.
Inflammation and Lipid Metabolism in the Liver
Early studies of the effects of LPS on lipoprotein metabolism
demonstrated that low doses of LPS stimulated hepatic de
novo fatty acid synthesis and lipolysis, both of which provided15, May 2, 2012 ª2012 Elsevier Inc. 639
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production (Figure 3) (Feingold et al., 1992b). The molecular
basis for this effect, which is observed within a few hours of
LPS treatment, has not been clearly established. Because LPS
injection induces numerous cytokines, including TNFa and
IL-1b, effects in liver could be primary responses to LPS,
secondary responses to cytokines, or both. De novo fatty acid
biosynthesis is primarily regulated by sterol response element
binding protein 1c (SREBP1c) (reviewed in Horton, 2002). Liver
X receptors induce expression of SREBP1c, as well as directly
regulate numerous genes involved in fatty acid biosynthesis
and metabolism (Repa et al., 2000; Schultz et al., 2000).
Increased production of fatty acids would therefore presumably
require activation of the SREBP pathway either at a transcrip-
tional or posttranscriptional level, but this has not been directly
shown in an LPS model. A recent study of TNFa in the livers of
fasting mice indicated that TNFa interferes with adaptation to
fasting and activates the insulin-Insig-SREBP signaling pathway
(Fon Tacer et al., 2007). Significant alterations were observed in
lipid homeostasis, including reduction of HDL cholesterol, an
increase in LDL cholesterol, and elevated expression of choles-
terogenic genes. This was accompanied by an increase of
precholesterol metabolites and suppression of cholesterol
elimination through bile acids. At the transcriptional level, a shift
in the expression of genes promoting fatty oxidation toward
those involved in fatty acid synthesis was observed. Consistent
with these studies, a different form of inflammatory stress
induced by casein injection increased hepatic cholesterol accu-
mulation and enhanced sterol regulatory element binding protein
2 (SREBP2), low-density lipoprotein receptor (LDLr) and
HMGCoA-reductase mRNA and protein expression in livers of
C57BL/6J mice and in HepG2 cells (Ma et al., 2008). In addition,
treatment of HepG2 cells with IL-6 or IL-1b increased nuclear
SREBP2, increased HMGCoA reductase protein levels, and
partially inhibited the normal feedback inhibition of the choles-
terol biosynthetic pathway in response to cholesterol loading
(Zhao et al., 2011). LPS-induced changes in the liver sinusoidal
endothelial cells predicted to reduce access of hepatocytes to
circulating lipoproteins has also been suggested to contribute
to hypertriglyceridemia (Cheluvappa et al., 2010). Hepatocyte
overexpression of IkB kinase b (IKKb), the major kinase required
for activation of NFkB downstream of Tlr, TNFa, and IL-1b
signaling, was recently shown to result in increased VLDL
synthesis (van Diepen et al., 2011), indicating that specific
activation of IKKb within hepatocytes is sufficient to induce
hypertriglyceridemia.
Many questions remain regarding the impact of inflammation
on lipid metabolism in the liver. Defining the mechanisms that
connect inflammatory signaling pathways to altered functions
of the SREBPs is of particular interest, as these mechanisms
might be amenable to therapeutic interventions. In addition,
there is a very limited understanding of the impact of inflamma-
tion on specific lipid species within broad lipid categories
(fatty acids, sterols, phospholipids, triglycerides, etc). Inflamma-
tory responses have the potential to reprogram lipid metabolic
pathways so as to change membrane properties, signaling
events, energy utilization, and other basic cellular processes.
The outcome of inflammatory stimuli on lipid metabolism may
also be influenced by the sterol and fatty acid composition of640 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.the diet, for example the relative content of u-3 and u-6 fatty
acids.
Inflammation and Lipid Metabolism in Muscle
Recent studies in human skeletal muscle, rodent skeletal
muscle, and skeletal muscle cell cultures using both gain- and
loss-of-function approaches provided evidence that Tlr4 sig-
naling reduces fatty acid oxidation (Frisard et al., 2010; Pang
et al., 2010) and that actions in muscle may contribute to
increased circulating triglycerides (Figure 3). Fasting animals
with a loss of Tlr4 function exhibited increased oxidative capacity
in skeletal muscle, lower levels of triglycerides and nonesterified
free fatty acids. Changes in substrate metabolism under condi-
tions of low (metabolic) LPS concentrations were suggested to
be independent of skeletal muscle-derived proinflammatory
cytokine production (Frisard et al., 2010).
One important consequence of inflammatory signaling in
muscle is an increase in production of ceramide, which, as
discussed above, may be a key intermediate that links inflamma-
tion to insulin resistance by blocking activation of Akt/PKB.
Studies in c2c12 myoblasts indicated that the LPS or saturated
fatty acid-induced ceramide production was associated with
IKKb-dependent upregulation of genes driving ceramide biosyn-
thesis. Importantly, increased ceramide production was not
required for Tlr4-dependent induction of inflammatory cytokines,
but it was essential for Tlr4-dependent insulin resistance
(Holland et al., 2011).
IL-6 is an inflammatory cytokine that is chronically elevated in
type 2 diabetes but also during exercise. Acute (4 hr) infusion of
physiological concentrations of IL4 into healthy human subjects
had no effects on glucose levels but increased systemic fatty
acid oxidation approximately 2-fold after 60 min, which re-
mained elevated by 2 hr after the infusion (Wolsk et al., 2010).
The increase in oxidation was followed by an increase in
systemic lipolysis. Adipose tissue lipolysis and fatty acid kinetics
were unchanged, but skeletal muscle unidirectional fatty acid
and glycerol release was increased, indicative of an increase in
lipolysis. The increased lipolysis in muscle could account for
the systemic changes. These effects in muscle were correlated
with activation of STAT3, a downstream target of IL-6, whereas
no changes in phosphorylated AMP-activated protein kinase or
acetyl-CoA carboxylase levels could be observed. IL-6 could
thus contribute to some of the observed changes in skeletal
muscle lipid metabolism seen in the context of Tlr4 activation,
acting as an autocrine factor or as a paracrine/endocrine factor
released by immune cells such as macrophages.
As in the case of the liver, inflammation induces substantial
changes in fatty acid metabolism in skeletal muscle, but the
mechanisms remain very poorly understood, and the impact
on classes of lipids beyond fatty acids and ceramides have not
been extensively evaluated. The differential effects of LPS and
IL-6 signaling underscore the complex nature of the ‘‘inflamma-
tory response,’’ which rather than being a single entity evolves as
a highly variable and context dependent process. IL-6 signaling
exerts effects on gene expression by controlling phosphorylation
of STAT3. Intriguingly, STAT3 has been shown to directly regu-
late the activities of the mitochondrial electron transport chain
in liver and heart, which could provide a connection between
effects of IL-6 signaling and fatty acid oxidation in skeletal
muscle (Wegrzyn et al., 2009).
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LPS, TNFa, and IL-1b induce lipolysis in primary adipocytes and
adipocyte cell lines, indicating a cell-autonomous effect that can
act independently of catecholamine-induced lipolysis (Figure 3)
(Feingold et al., 1992a; Franchini et al., 2010; Kawakami et al.,
1987; Ryden et al., 2002; Zhang et al., 2002; Zu et al., 2008).
Inhibitor studies suggest that TNFa increases lipolysis in adipo-
cytes by activation of mitogen-activated protein kinase kinase
(MEK), extracellular signal-related kinase (ERK), and Jun
N-terminal kinase (JNK) and elevation of intracellular cAMP
leading to activation of PKA, with some variations in relative
importance observed dependent on the specific cellular system
used (Ryden et al., 2002; Zhang et al., 2002). PKA activation
directly affects lipolysis by phosphorylating the lipid droplet
associated protein perilipin (Granneman et al., 2007). This results
in release of CGI-58/Abhd5, which binds to and coactivates
adipose triglyceride lipase (ATGL) (Granneman et al., 2009).
ATGL has recently been shown to be the major lipase respon-
sible for TNFa-induced lipolysis in 3T3L1 adipocytes (Yang
et al., 2011). These studies also provided evidence that TNFa
signaling profoundly suppresses the expression of G0S2, a
recently identified endogenous inhibitor of ATGL. Thus, TNFa
signaling acts simultaneously to stimulate activators and sup-
press inhibitors of ATGL activity. Given the central importance
of triglyceride hydrolysis in adipose tissue, liver, and skeletal
muscle in overall fatty acid metabolism, it will be of great interest
to explore the importance of these regulatory pathways in each
tissue in vivo. Intriguingly, salicylates block the lipolytic response
to TNFa (Zu et al., 2008), an effect that may contribute to their
insulin-sensitizing activities.
The production of TNFa and IL-1b could potentially account for
the effects of LPS on adipose tissue lipolysis, but the use
of adrenergic or interleukin-1 receptor antagonists and TNFa-
neutralizing antibodies did not abolish increases in serum levels
of FFA and triglycerides in endotoxemic rats (Feingold et al.,
1992b; Nonogaki et al., 1994). Notably, neither adipocytokine
secretion nor NFkB activation is involved in endotoxin-induced
lipolysis (Zu et al., 2009). In contrast to catecholamines and
TNFa, endotoxin stimulates lipolysis without elevating cAMP
production and activating protein kinase A and protein kinase
C. Instead, endotoxin induces phosphorylation of Raf-1, MEK1/
2, and ERK1/2. Upon inhibition of ERK1/2 but not JNK and p38
MAPK, endotoxin-stimulated lipolysis ceases. Endotoxin causes
downregulation and phosphorylation of perilipin, which would be
expected to result in activation of ATGL by CGI-58.
Intriguingly, recent studies have found that deletion of BLT1,
a receptor for leukotriene B4 (LTB4), protects mice from
high-fat diet-induced insulin resistance (Spite et al., 2011).
BLT1-deficient mice exhibited a marked reduction in accumula-
tion of classically activated adipose tissue macrophages and
a reduction in proinflammatory cytokines. Although LTB4 itself
was not directly measured in these assays, these findings sug-
gest that the proinflammatory response of adipose tissue to a
high-fat diet results in LTB4 production from arachidonic acid,
which serves to recruit LTB4-positive monocytes into adipose
tissue. Pharmacological blockade of BLT1 might thus have
insulin-sensitizing effects in the context of obesity.
Interferon regulatory factor 4 (IRF4), which plays key roles in
regulation of function of immune cells, was recently shown toregulate the transcriptional response to nutrient availability in
adipocytes. Fasting induces IRF4 in an insulin- and FoxO1-
dependent manner. IRF4 is required for lipolysis, at least in
part due to direct effects on the expression of ATGL and
hormone-sensitive lipase. Conversely, reduction of IRF4
enhances lipid synthesis (Eguchi et al., 2011).
The extent to which inflammation-driven lipolysis in adipose
tissue contributes to insulin resistance remains to be clearly es-
tablished. The influence of free fatty acids on inflammation,
described above, and the proximity of adipose tissue macro-
phages to lipolysis-generated FFAs suggests the possibility of
a local positive feedback loop that amplifies insulin resistance.
It will therefore be of interest to evaluate the consequences of in-
hibiting lipolysis on inflammation and insulin resistance in vivo.
Inflammation and Lipid Metabolism in the Macrophage
Based on the key pathogenic roles of macrophages and Tlrs in
the development of atherosclerosis (Moore and Tabas, 2011)
and diabetes (Olefsky and Glass, 2010), the LIPID MAPS con-
sortium recently reported a comprehensive analysis of the
effects of Tlr4 signaling on the lipidome and transcriptome of
RAW264.7 macrophages (Dennis et al., 2010). These studies
demonstrated immediate responses in fatty acid metabolism,
represented by increases in eicosanoid synthesis, and delayed
responses characterized by alterations in sphingolipid and sterol
biosynthesis. Tlr4 activation generated increases in almost every
category of sphingolipid analyzed, including free sphingoid
bases and their phosphates (e.g., sphingosine-1-phosphate),
ceramides, sphingomyelins, and glycosphingolipids. It would
not be surprising for inflammatory signaling to have similar
effects on the lipidomes of other metabolically important cell
types, including adipocytes, hepatocytes, and skeletal muscle
cells. Consistent with this, the impact of Tlr4 signaling on ceram-
ide production in RAW264.7 cells and C2C12 skeletal muscle
cells is similar (Holland et al., 2011). Notably, lipid remodeling
of glycerolipids, glycerophospholipids, and prenols was also
observed in activated RAW264.7 cells, indicating that Tlr4
signaling leads to alterations in a majority of mammalian lipid
categories (Dennis et al., 2010). Thus, it is likely that extension
of these methods to primary cells and tissues would be highly
informative. Along these lines, a recent lipidomic analysis of
adipose tissue macrophages from ob/ob mice indicates that
macrophage triglycerides accumulate during the transition
from insulin-sensitive to obese/insulin resistance. Treatment
with a PPARg agonist prevented triglyceride accumulation in
these cells (Prieur et al., 2011).
Signaling Pathways that Connect Inflammation
to Lipid Metabolism
The Tlr, IL-1b, and TNFa signaling pathways are best understood
with respect to their roles in initiation and amplification of innate
immune responses through the activation of latent transcription
factors that include members of the NFkB, AP-1, and IRF gene
families. Much less is known, however, with respect to themech-
anisms by which inflammatory signaling pathways affect lipid
metabolism. Regulation of posttranslational modifications, e.g.,
perilipin phosphorylation, is likely to play an important role. In
addition, significant effects of inflammatory signaling pathways
on the expression and function of transcription factors that
regulate lipid homeostasis have been identified. For example,
Tlr4 activation is a potent suppressor of PPARg expression inCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 641
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LXR function by a mechanism that involves the TRIF adaptor
protein (Castrillo et al., 2003). It will be of interest to explore
whether inflammatory signaling influences the expression or pro-
cessing of the SREBP transcription factors that play central roles
in fatty acid and cholesterol biosynthesis. A large number of
other transcription factors also influence lipid metabolism,
including PPARa, PPARd, Forkhead transcription factors,
KLFs, and others. The emergence of sensitive and quantitative
methods to measure major and minor lipid species by mass
spectroscopy, coupled with genome-wide measurement of
gene expression, are likely to provide important new insights
into the relationships between inflammation, lipid metabolism,
and disease in the years ahead.
Conclusions
Striking progress has been made in the last few years in decon-
voluting the complex relationships between lipid metabolism
and inflammation that contribute to metabolic disease. In partic-
ular, new molecular mechanisms accounting for proinflamma-
tory effects of saturated FFAs and anti-inflammatory effects of
u-3 PUFAs have been discovered. In addition, the production
of ceramide in response to inflammatory signaling in skeletal
muscle and macrophages is emerging as an important mecha-
nism contributing to insulin resistance. At the level of the impact
of inflammation on lipid metabolism, recent studies have uncov-
ered likely molecular mechanisms by which inflammatory medi-
ators such as LPS and TNFa function to stimulate lipolysis in
adipose tissue, through the indirect regulation of ATGL. Studies
extending the analysis of these mechanisms in vivo should be
productive lines of investigation for the future. Many aspects of
the relationship between inflammation and lipid metabolism
remain poorly understood. In particular, mechanisms by which
inflammatory signaling regulates the functions of SREBPs,
LXRs, and PPARs remain almost completely unknown and are
potential targets for therapeutic intervention. The ability to inves-
tigate the extent to which inflammation reprograms lipid metab-
olism to alter the production, catabolism, and interconversion of
specific lipid species has until recently been significantly limited
by technology. The recent development of improved instrumen-
tation and methodologies for analysis of diverse lipid species by
mass spectrometry is now enabling substantial efforts to under-
stand how the lipidome is regulated at a more global level. It will
be of particular interest to bring the combination of lipidomics
and transcriptomics to the analysis of the impact of dietary
interventions on lipid metabolism in key metabolic organs. Fatty
acid composition of the diet can varywidely, frombeing relatively
high in saturated (animal-derived) FFAs such as palmitic acid
that have direct proinflammatory effects, to relatively high in
u-6 (e.g., corn oil-derived) FFAs such as linoleic acid that can
be further elongated, desaturated and converted to proinflam-
matory prostaglandins, to relatively high in u-3 (e.g., fatty fish
and certain seed oil-derived) FFAs that exert anti-inflammatory
effects. As there is now substantial interest in the agricultural
and food products industries to develop new food oils and
food products with increased levels of u-3 PUFAs, the rationale,
specific form, and advisability of these efforts should rest on
a deeper knowledge of the relationship between lipid metabo-
lism, inflammation, and disease.642 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.ACKNOWLEDGMENTS
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